FINWIRES · TerminalLIVE
FINWIRES

クレセント・エナジー、石油・ガス販売量の増加に支えられ第1四半期決算を発表

By

-- クレセント・エナジー・カンパニー(CRGY)は月曜日、第1四半期決算を発表し、日平均純販売量が34万1000バレル相当(石油換算)となり、前年同期の25万8000バレル相当から増加したことを報告した。 クレセントは、日平均純販売量の市場予想である32万8000バレル相当を約4%上回ったと報告した。 同社は、3月31日締めの四半期における日平均石油純販売量が14万バレルとなり、前年同期の10万2000バレル相当から増加したと報告した。 天然ガスの日平均純販売量は、同四半期で7億4300万立方フィートとなり、前年同期の6億5500万立方フィート相当から増加したと報告した。 また、天然ガス液の日平均純販売量は7万7000バレルとなり、前年同期の4万7000バレル相当から増加したと報告した。クレセント・エナジーは、パーミアン盆地の統合により、当初の目標を上回る約1億2000万ドルのコスト削減を達成したと発表した。 同社は第1四半期に38坑の操業井を掘削し、37坑を稼働させた。また、同四半期の設備投資額は3億8500万ドルに達した。 クレセント・エナジーは2026年第1四半期に、イーグルフォード鉱区における鉱物資源の買収を2件完了し、総額約3億5500万ドルを投じた。これにより、未開発資源へのエクスポージャーを拡大し、ポートフォリオを拡充した。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX